Novo Nordisk (NVO), the obesity drug maker, fell -13% to $48.85. It warned fiscal 2026 adjusted sales will decline between 5% and 13%. Lower US drug prices and a reversal of rebate provisions hurt its outlook. Fourth-quarter sales dropped 2%. Fiscal 2025 sales rose about 10%.